Liver Cirrhosis, Experimental
|
0.300 |
Biomarker
|
disease |
CTD_human |
Systems level analysis and identification of pathways and networks associated with liver fibrosis.
|
25380136 |
2014 |
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
RNAi knockdown of KDM5B induced HEXIM1 expression, thus validating the specific negative regulation of tumor suppressor HEXIM1 by the H3K4me3/2 demethylase KDM5B.
|
31805991 |
2019 |
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
We previously reported that the tumor suppressor HEXIM1 is a mediator of KDM5B recruitment to its target genes, and HEXIM1 is required for the inhibition of nuclear hormone receptor activity by KDM5B.
|
31776402 |
2019 |
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
HEXIM1 is described as an excellent pharmacodynamic biomarker for target engagement in tumors as well as in blood.
|
29491412 |
2018 |
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Our findings suggest the potential of ubenimex adjuvant treatment to enhance JQ1 efficiency and attenuate parts of its side effect (enhancing tumor aggressive) by regulating the autophagic degradation of HEXIM1 and Akt inhibition.
|
28484091 |
2017 |
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
HEXIM1 as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues.
|
27903752 |
2017 |
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
In melanoma, we identify HEXIM1, a transcription elongation regulator, as a melanoma tumor suppressor that responds to nucleotide stress.HEXIM1 expression is low in melanoma.
|
27058786 |
2016 |
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Nucleotide stress induces the tumor suppressor HEXIM1 to suppress melanoma.
|
27102073 |
2016 |
Neoplasms
|
0.090 |
AlteredExpression
|
group |
BEFREE |
We have been studying the role of Hexamethylene bisacetamide (HMBA) Induced Protein 1 (HEXIM1) as a tumor suppressor whose expression is decreased in tamoxifen resistant and metastatic breast cancer.
|
27238569 |
2016 |
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
Sphingosine kinase 1 promotes tumour cell migration and invasion via the S1P/EDG1 axis in hepatocellular carcinoma.
|
22098666 |
2012 |
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Known inhibitors of KDM5B were also able to induce HEXIM1 expression, inhibit cell proliferation, induce differentiation, potentiate sensitivity to cancer chemotherapy, and inhibit breast tumor metastasis.
|
31805991 |
2019 |
Primary malignant neoplasm
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Known inhibitors of KDM5B were also able to induce HEXIM1 expression, inhibit cell proliferation, induce differentiation, potentiate sensitivity to cancer chemotherapy, and inhibit breast tumor metastasis.
|
31805991 |
2019 |
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Utility of HEXIM1 mRNA may be limited to higher concentrations.<i>Clin Cancer Res; 23(4); 1025-35.©2017 AACR</i>.
|
28073847 |
2017 |
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Incorporating well-characterized pharmacodynamic markers, such as HEXIM1 and other genes described here, can provide a better understanding of potential efficacy and toxicity associated with inhibiting BET family proteins and informs early clinical decisions on BET inhibitor development programs.Mol Cancer Ther; 16(2); 388-96.©2016 AACR.
|
27903752 |
2017 |
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Decreased Hexim-1 expression in animal models of chronic diseases such as left ventricular hypertrophy, obesity and cancer triggered significant changes in adaptation and remodeling.
|
28013147 |
2017 |
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
Incorporating well-characterized pharmacodynamic markers, such as HEXIM1 and other genes described here, can provide a better understanding of potential efficacy and toxicity associated with inhibiting BET family proteins and informs early clinical decisions on BET inhibitor development programs.Mol Cancer Ther; 16(2); 388-96.©2016 AACR.
|
27903752 |
2017 |
Primary malignant neoplasm
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Decreased Hexim-1 expression in animal models of chronic diseases such as left ventricular hypertrophy, obesity and cancer triggered significant changes in adaptation and remodeling.
|
28013147 |
2017 |
Primary malignant neoplasm
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Utility of HEXIM1 mRNA may be limited to higher concentrations.<i>Clin Cancer Res; 23(4); 1025-35.©2017 AACR</i>.
|
28073847 |
2017 |
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
HEXIM1 plays an important role in inhibiting cancer cell-specific gene transcription while also facilitating anti-cancer gene expression.
|
27058786 |
2016 |
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
HEXIM1 plays an important role in inhibiting cancer cell-specific gene transcription while also facilitating anti-cancer gene expression.
|
27058786 |
2016 |
Malignant Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
HEXIM1 and the control of transcription elongation: from cancer and inflammation to AIDS and cardiac hypertrophy.
|
17671421 |
2007 |
Primary malignant neoplasm
|
0.060 |
AlteredExpression
|
group |
BEFREE |
HEXIM1 and the control of transcription elongation: from cancer and inflammation to AIDS and cardiac hypertrophy.
|
17671421 |
2007 |
Neoplasm Metastasis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Increased HEXIM1 expression caused differentiation and inhibited proliferation and metastasis of cancer cells.
|
31805991 |
2019 |
Mammary Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Known inhibitors of KDM5B were also able to induce HEXIM1 expression, inhibit cell proliferation, induce differentiation, potentiate sensitivity to cancer chemotherapy, and inhibit breast tumor metastasis.
|
31805991 |
2019 |
Malignant neoplasm of breast
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Molecular target identification of HMBA and 4a1 could lead to further structural optimization of the parental compound to generate more potent derivatives to stimulate HEXIM1 expression, which could be a novel approach for hormone dependent breast cancer and prostate cancer treatment.
|
28213333 |
2017 |